DE60316411D1 - Thiazolderivate als npy-rezeptorantagonisten - Google Patents

Thiazolderivate als npy-rezeptorantagonisten

Info

Publication number
DE60316411D1
DE60316411D1 DE60316411T DE60316411T DE60316411D1 DE 60316411 D1 DE60316411 D1 DE 60316411D1 DE 60316411 T DE60316411 T DE 60316411T DE 60316411 T DE60316411 T DE 60316411T DE 60316411 D1 DE60316411 D1 DE 60316411D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
npy receptor
thiazone
derivatives
thiazone derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60316411T
Other languages
English (en)
Other versions
DE60316411T2 (de
Inventor
Patrizio Mattei
Werner Neidhart
Matthias Heinrich Nettekoven
Philippe Pflieger
Sven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60316411D1 publication Critical patent/DE60316411D1/de
Publication of DE60316411T2 publication Critical patent/DE60316411T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
DE60316411T 2002-02-28 2003-02-19 Thiazolderivate als npy-rezeptorantagonisten Expired - Fee Related DE60316411T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02004296 2002-02-28
EP02004296 2002-02-28
PCT/EP2003/001667 WO2003072577A1 (en) 2002-02-28 2003-02-19 Thiazole derivatives as npy receptor antagonists

Publications (2)

Publication Number Publication Date
DE60316411D1 true DE60316411D1 (de) 2007-10-31
DE60316411T2 DE60316411T2 (de) 2008-06-12

Family

ID=27763338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316411T Expired - Fee Related DE60316411T2 (de) 2002-02-28 2003-02-19 Thiazolderivate als npy-rezeptorantagonisten

Country Status (21)

Country Link
US (1) US6686381B2 (de)
EP (1) EP1480976B1 (de)
JP (1) JP2005526732A (de)
KR (1) KR100611854B1 (de)
CN (1) CN100363362C (de)
AR (1) AR038704A1 (de)
AT (1) ATE373654T1 (de)
AU (1) AU2003210305B2 (de)
BR (1) BR0308108A (de)
CA (1) CA2475299A1 (de)
DE (1) DE60316411T2 (de)
ES (1) ES2292992T3 (de)
GT (1) GT200300045A (de)
MX (1) MXPA04008379A (de)
PA (1) PA8567301A1 (de)
PE (1) PE20030930A1 (de)
PL (1) PL372463A1 (de)
RU (1) RU2004129285A (de)
TW (1) TW200403995A (de)
UY (1) UY27689A1 (de)
WO (1) WO2003072577A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
EP1656374B1 (de) 2003-08-12 2009-03-11 F. Hoffmann-La Roche Ag Thiazolderivate als npy-antagonisten
BRPI0413500A (pt) 2003-08-12 2006-10-10 Hoffmann La Roche compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
DE602004011394T2 (de) 2003-12-08 2009-01-08 F. Hoffmann-La Roche Ag Thiazolderivate
US7820704B2 (en) * 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
WO2010098298A1 (ja) * 2009-02-27 2010-09-02 塩野義製薬株式会社 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
EP4084779A1 (de) 2019-12-30 2022-11-09 Deciphera Pharmaceuticals, LLC Zusammensetzungen von 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylharnstoff
CA3163053A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AUPN163795A0 (en) 1995-03-10 1995-04-06 DIPNALL, David A device for extracting energy from moving water particles
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
CA2340052C (en) 1998-08-14 2007-05-29 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
DE69924999T2 (de) 1998-08-14 2006-05-04 F. Hoffmann-La Roche Ag Lipasehemmer enthaltende pharmazeutische zusammensetzungen
US20010039275A1 (en) * 2000-02-04 2001-11-08 Bowler Andrew Neil Use of 2,4-diaminothiazole derivatives
WO2001064675A1 (en) * 2000-03-03 2001-09-07 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
MXPA04000906A (es) * 2001-08-03 2004-11-22 Novo Nordisk As Nuevos derivados de 2,4-diaminotiazol.

Also Published As

Publication number Publication date
CN100363362C (zh) 2008-01-23
WO2003072577A1 (en) 2003-09-04
CA2475299A1 (en) 2003-09-04
JP2005526732A (ja) 2005-09-08
KR20040094735A (ko) 2004-11-10
TW200403995A (en) 2004-03-16
EP1480976A1 (de) 2004-12-01
US6686381B2 (en) 2004-02-03
RU2004129285A (ru) 2005-10-27
AU2003210305A1 (en) 2003-09-09
ATE373654T1 (de) 2007-10-15
MXPA04008379A (es) 2004-11-26
US20030225141A1 (en) 2003-12-04
UY27689A1 (es) 2003-08-29
PE20030930A1 (es) 2003-11-08
AU2003210305B2 (en) 2006-07-06
BR0308108A (pt) 2004-12-07
CN1639158A (zh) 2005-07-13
GT200300045A (es) 2003-09-23
KR100611854B1 (ko) 2006-08-11
DE60316411T2 (de) 2008-06-12
AR038704A1 (es) 2005-01-26
ES2292992T3 (es) 2008-03-16
PA8567301A1 (es) 2004-02-07
PL372463A1 (en) 2005-07-25
EP1480976B1 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
CY2017032I1 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE413400T1 (de) Cgrp-rezeptorantagonisten
DE60320529D1 (de) Chinolinderivate als npy antagonisten
DK1951660T3 (da) Histamin-3-receptorantagonister
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE494285T1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
NO20051871D0 (no) Opioid reseptorantagonister
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE462688T1 (de) Diarylsulfone als 5-ht2a-antagonisten
DE602004004278D1 (de) 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
ATE403651T1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
ATE425161T1 (de) Mercaptoimidazole als ccr2-rezeptorantagonisten
ATE495168T1 (de) Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten
ATE504300T1 (de) Harnstoffderivate als il-8-rezeptorantagonisten
ATE411989T1 (de) Mercaptoimidazole als ccr2-rezeptorantagonisten
ATE528291T1 (de) Cyclopropylderivate als nk3 rezeptor-antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee